Exhibit 99.1

Esperion Corporate Presentation © 2025 Esperion Therapeutics, Inc. All rights reserved. October 2025

2 © 2025 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures This pre s e ntation c ontains forward-looking s tate me nts of Es pe rion The rape utic s , Inc . (“Es pe rion,” “we ,” or “our”) that are made purs uant to the s afe harbor provis ions of the fe de ral s e c uritie s laws , inc luding s tate me nts re garding marke ting s trate gy and c omme rc ialization plans , c urre nt and planne d ope rational e xpe ns e s , e xpe cte d profitability, future ope rations , c omme rc ial produc ts , c linic al de ve lopme nt, plans for pote ntial future produc t c andidate s , financ ial c ondition and outlook, inc luding e xpe c te d c as h runway and profitability, and othe r s tate me nts c ontaining the words “antic ipate ,” “be lie ve ,” “e s timate ,” “e xpe c t,” “inte nd,” “may,” “plan,” “pre dic t,” “proje c t,” “s ugge s t,” “targe t,” “pote ntial,” “will,” “would,” “c ould,” “s hould,” “c ontinue ,” and s imilar e xpre s s ions . Any e xpre s s or implie d s tate me nts c ontaine d in this pre s e ntation that are not s tate me nts of his toric al fac t may be de e me d to be forward-looking s tate me nts. Forward-looking s tate me nts involve ris ks and unc e rtaintie s that c ould c aus e Es pe rion’s ac tual re s ults to diffe r s ignific antly from thos e proje c te d, inc luding, without limitation, the ne t s ale s , profitability, and growth of Es pe rion’s c omme rc ial produc ts , c linic al ac tivitie s and re s ults , s upply c hain, c omme rc ial de ve lopme nt and launc h plans , the outc ome s and antic ipate d be ne fits of le gal proc e e dings and s e ttle me nts , and the ris ks de taile d in Es pe rion’s filings with the Se c uritie s and Exc hange Commis s ion (the “SEC”), inc luding in Es pe rion’s mos t re c e nt Annual Re port on Form 10-K and in any s ubs e que nt filings with the SEC. Any forward-looking s tate me nts c ontaine d in this pre s e ntation s pe ak only as of the date he re of, and Es pe rion dis c laims any obligation or unde rtaking to update or re vis e any forward-looking s tate me nts c ontaine d in this pre s e ntation, othe r than to the e xte nt re quire d by law. No re pre s e ntations or warrantie s (e xpre s s e d or implie d) are made about the ac c urac y of any s uc h forward-looking s tate me nts . Ce rtain information c ontaine d in this pre s e ntation re late s to or is bas e d on s tudie s , public ations , s urve ys and othe r data obtaine d from third-party s ourc e s and Es pe rion’s own inte rnal e s timate s and re s e arc h. While Es pe rion be lie ve s the s e third-party s tudie s , public ations , s urve ys and othe r data to be re liable as of the date of this pre s e ntation, Es pe rion has not inde pe nde ntly ve rifie d, and make no re pre s e ntation as to the ade quac y, fairne s s , ac c urac y or c omple te ne s s of, any information obtaine d from third-party s ourc e s . In addition, no inde pe nde nt s ourc e has e valuate d the re as onable ne s s or ac c urac y of Es pe rion’s inte rnal e s timate s or re s e arc h and no re lianc e s hould be made on any information or s tate me nts made in this pre s e ntation re lating to or bas e d on s uc h inte rnal e s timate s and re s e arc h. Finally, Es pe rion has not c onduc te d any he ad-to-he ad s tudie s c omparing its produc t c andidate s to any third party drug produc ts or c andidate s , whe the r inve s tigate d or approve d. Information re garding othe r drug produc ts in this pre s e ntation is me ant to provide c onte xt for illus trative purpos e s only. Be c aus e the re are no head-to-he ad s tudie s , no c onc lus ions s hould be made bas e d on c ros s s tudy c omparis ons . Re c ipie nts are c autione d not to plac e undue re lianc e on the s e forward looking s tate me nts , whic h s pe ak only as of the date s uc h s tate me nts are made and s hould not be c ons true d as statements of fact.

Clear Strategic Plan for Success © 2025 Esperion Therapeutics, Inc. All rights reserved. 3 Expand Bempedoic Acid Franchise Globally • Key ANDA settlements provide the potential to secure additional years of exclusivity, extending blockbuster revenue potential • Settlement agreements for April 19, 2040 reached with: • Dr. Reddy’s Laboratories • Micro Labs USA, Inc. • Hetero USA Inc. • Accord Healthcare Inc. • Deploying a balanced in-person and digital engagement strategy that has accelerated physician adoption – and serve as a driver for growth • Leveraging global partnerships to support meaningful revenue growth and expand market awareness worldwide Transition to Cash Generating Pharmaceutical Company Pipeline Advancement and Portfolio Expansion • Advancing our internally developed and wholly owned development pipeline • Advancing development of triple combination products in the U.S. to unlock additional growth opportunities • Potential acquisition or in-licensing of cardiometabolic products that are synergistic with our commercial call point • Operating income from ongoing business in the second quarter 2025 supports expectations for sustainable profitability • Revenue growth from expanding product adoption and geographic reach supporting profitability objectives ANDA – Abbreviated New Drug Application

Strategic Priorities 4 © 2025 Esperion Therapeutics, Inc. All rights reserved. Expand Bempedoic Acid Franchise Globally • Invest in targeted marketing initiatives to accelerate physician adoption and broaden patient access • Expand reach of sales team through targeted territory additions and enhanced patient activation programs • Increase consumer awareness and drive demand through consumer-activated educational initiatives • Lay the foundation for sustained growth, positioning the franchise for multiple years of blockbuster status Transition to Cash Generating Pharmaceutical Company Pipeline Advancement and Portfolio Expansion • Drive clinical development of PSC program • Accelerate kidney program development to expand potential therapeutic impact • Advance label-expanding trials for the triple combination therapy • Support potential acquisition or in-licensing of complementary assets to drive long-term growth • Cementing the path to profitability • Enhancing long-term cash generation potential through a potentially lengthened exclusivity period

Financial Highlights 5 © 2025 Esperion. All Rights Reserved – Do not copy or distribute. 0 10 20 30 40 50 60 70 80 90 Q1 2025 Q2 2025 65.0 Total Net Revenue (in $MM) +27% 0 5 10 15 20 25 30 35 40 45 Q1 2025 Q2 2025 35.0 U.S. Product Revenue (in $MM) +15% 0 5 10 15 20 25 30 35 40 Q1 2025 Q2 2025 30.1 Collaboration Revenue (in $MM) +40% 82.4 40.3 42.1 Cash & Cash Equivalents $86.1M as of June 30, 2025 Q2 2025 First Quarter of Operating Income from Ongoing Business in Company’s History

- 20,000 40,000 60,000 80,000 100,000 120,000 140,000 160,000 180,000 200,000 220,000 240,000 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Strong Prescription Trend and Increasing Physician Adoption Continue to Drive Durable Revenue Growth © 2025 Esperion Therapeutics, Inc. All rights reserved. 6 Quarterly Franchise Retail Prescription Equivalents (RPE) Trend Weekly Franchise RPE Trend1 1. Through June 30, 2025. +10% RPE Growth - 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 20,000 1/6/23 1/6/24 1/6/25

Driving U.S. and Global Growth and Reaching Profitability

1. Shen M, et al. J Am Heart Assoc, 2022;11:3026075. 2. Metser G. et al. Am J Cardiol. 2021;161:36-41 . 3.Allen JM, et al. Circulation. 2019;140:A12904. 4. Yang Y, et al. Circulation. 2021;144:A10434. 5. Wong ND, et al. J Clin Lipid.2016;10:1109-1118. 6. Cheeley MK, et al. J Clin Lipidol. 2022 Jul-Aug;16(4):361-375. 7. Ahmad FB, Anderson RN. JAMA. 2021;325(18):1829- 1830. 8. Tsao C, et al. Circulation. 2023;147:e93-e621. 9. Int J Environ Res Public Health. 2022 Jul 6;19(14):8272. doi: 10.3390/ijerph19148272.10. Gu J, et al. Am J Prev Cardiol. 2022 Mar 20;10:100336. Despite Statins, an Ongoing Medical Need for Oral Therapies Remains © 2025 Esperion Therapeutics, Inc. All rights reserved. 8 ~44% ~53% of US adults with, or at risk for, CVD are not at recommended LDL-C levels3,4,5 High levels of LDL-C are the main risk factor for CVD9 CVD remains a leading health risk in US men and women7,8 of US adults are at high-risk or have experienced a CV event1,2 Statins alone are not enough to optimize LDL-C and prevent CVD10 ~30% of US adults are unable to take recommended statin therapy 6 Marketing & Sales Strategic Focus Area: Our near-term priority population LDL-C: Low-Density Lipoprotein Cholesterol CVD: Cardiovascular Disease

1. Allen JM, et al. Circulation. 2019;140:A12904. 2. Shen M, Nargesi AA, et al. J Am Heart Assoc. 2022;11:e026075. 3. Yang Y, et al. Circulation. 2021;144:A10434. 4. Wong ND, et al. J Clin Lipidology. 2016;10:1109-1118. 5. Bytyci I, et al. Eur Heart J. 2022;00:1-16. 6. Total U.S. Resident Population by Age, Sex, and Series: April 1, 2020 [table]; US Census Bureau: 2020. 7. Symphony Data as of Dec 31, 2024. Significant and Growing U.S. Market Opportunity © 2025 Esperion Therapeutics, Inc. All rights reserved. 9 Over 70 million at-risk patients are undertreated or not treated Rising need drives double-digit growth in the non-statin market Branded non-statin therapies are leading growth in the non-statin market Non-Statin Prescription Volume7 13.0M 14.9M 17.7M 21.1M 10 12 14 16 18 20 22 2021 2022 2023 2024 TRx, Millions Branded Non-Statin Prescription Volume7 2.7M 3.2M 4.0M 5.2M 0 1 2 3 4 5 6 2021 2022 2023 2024 TRx, Millions ~10M Under-Treated High-Risk Primary Prevention & ASCVD Patients2,3,4,5 Under-Treated ASCVD Patients1 + ~20M + ~40M Untreated High-Risk Primary Prevention & ASCVD Patients 1,2,5,6 +14.6% +18.6% +18.0% +19.7% +26.7% +29.5%

Bempedoic Acid Received 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias 10 © 2025 Esperion Therapeutics, Inc. All rights reserved. • Bempedoic acid was the only new non-statin included with LDL-C and CV risk reduction data. • First time a guideline has given a Level IA to recommend combination therapy based on magnitude of LDL-C reduction needed. Strike early, strike strong Recommendations Class Level Non-statin therapies with proven cardiovascular benefit (including bempedoic acid), taken alone or in combination, are recommended for patients who are unable to take statin therapy to lower LDL-C levels and reduce the risk of CV events. The choice should be based on the magnitude of additional LDL-C lowering needed. I A Bempedoic acid is recommended in patients who are unable to take statin therapy to achieve the LDL-C goal. I B The addition of bempedoic acid to the maximally tolerated dose of statin with or without ezetimibe should be considered in patients at high or very high risk in order to achieve the LDL-C goal. IIa C European Guidelines Expected to Inform Upcoming U.S. Cholesterol Treatment Guidelines

Filling the Treatment Gap: Our Breakthrough in LDL-C Management © 2025 Esperion Therapeutics, Inc. All rights reserved. 11 Ezetimibe STATINS NON-STATIN THERAPIES • Mostly generic • First-line, widely used • Combinable for incremental LDL-lowering • 25-55% drops in LDL-C CV Risk Reduction Indication 1 LDL-C Lowering 2 Primary Prevention Secondary Prevention Use Without a Statin PCSK9i mAbs PCSK9i siRNA Observed LDL-C Reduction 19% 17-18% 38% Administration 48-71% 48-52% 1. Variations within the specific wording of each product indication. No head-to-head studies have been conducted; cross-study data reflect different study designs, populations, and other features.

The Next Step in Cardiovascular Risk Reduction 12 CV Risk Reduction 27% Nonfatal MI Coronary Revascularization 19% CLEAR Outcomes Primary Prevention* 32% MACE-4 (nonfatal MI, coronary revascularization, nonfatal stroke, or CV death) LDL-C Reduction 38% Not activated in skeletal muscle Does not raise glucose Reduces hsCRP Use with or without a statin HR, 0.73 (95% CI: 0.62-0.87) HR, 0.81 (95% CI: 0.72-0.92) HR, 0.68 (95% CI: 0.53-0.87) The primary endpoint was percent change from baseline to Week 12 in LDL-C. Results shown are based on a mean 38% placebo-corrected LDL-C reduction (-36% NEXLIZET vs +2% placebo) RRR 30% of patients enrolled have not had their first event but are at high risk RRR RRR © 2025 Esperion Therapeutics, Inc. All rights reserved. * - As pre-specified exploratory analysis

Strengthening Access and Driving Growth 13 © 2025 Esperion Therapeutics, Inc. All rights reserved. • 10% increase in total retail prescription equivalents vs. Q1 2025 • Now over 28,000 total HCPs • 23% of prescriptions written by physicians with only digital touchpoints • 38% of new writer prescriptions were driven by digital only touchpoints • Approval rates of more than 80% following education of 1,100+ target prescribers by our expanded U.S. fields reimbursement team Expanded payer coverage and reduced prior authorization requirements Q2 2025 Resulted in: Enhanced reimbursement support resources for patients and providers Balanced direct and digital marketing approach

Strategic Partnerships Driving Billion $ Global Opportunity © 2025 Esperion Therapeutics, Inc. All rights reserved. 14 Partner Daiichi Sankyo Europe Asia & South America Daiichi Sankyo Co., Ltd. Otsuka Pharmaceutical Co., Ltd. Agreement Terms Neopharm Israel HLS Therapeutics Tiered royalties and additional sales milestones • Received approval in Q3 2025 • National Health Insurance pricing approval in Q4 2025 Europe Maximizing Global Reach Across Key Regions Japan Tiered royalties, regulatory, pricing and additional sales milestones Tiered royalties and additional sales milestones • Launched in many key markets including Germany, UK, Austria, Belgium, Switzerland, Italy, Spain, Netherlands, Slovakia and Czech Republic to date • Expanded label approved in EU and UK in May/June ’24 Highlights • Received regulatory approval to market product (mono & dual) and launched: • Hong Kong in 2023 • Thailand and Macau in 2024 • Received regulatory approval to market product (mono) • Myanmar and Taiwan in 2024 Israel Canada Tiered royalties and additional milestones • Filed NDA for marketing approval in Q1 2025; approval anticipated in the first half of 2026 • Expect market approval in Q4 2025 Upfront Payment, Milestones and Tiered Royalties 40 Approved in countries globally A p p r o v a l a n d l a u n c h i n a d d i t i o n a l t e r r i t o r i e s a n t i c i p a t e d i n Q 4 2 0 2 5 a n d b e y o n d Australia & New Zealand CSL Seqirus Upfront and near-term milestone payments • Filed marketing application in Australia in July 2025 • Expect market approval in Q4 2026

Pipeline Advancement

Renal Diseases To Be Announced Primary Sclerosing Cholangitis (PSC) IND: 2026 PRODUCT/PROGRAM EXPLORATORY LEAD ID LEAD OPTIMIZATION PRECLINICAL DEVELOPMENT CLINICAL DEVELOPMENT APPROVED / COMMERCIAL MILESTONES Proven Science, Innovative Pipeline 16 © 2025 Esperion Therapeutics, Inc. All rights reserved. I n n o v a t i v e P o r t f o l i o & P i p e l i n e NEXLETOL® bempedoic acid Approved 2020 Expanded label 2024 NEXLIZET® bempedoic acid and ezetimibe Approved 2020 Expanded label 2024 Triple Combination A bempedoic acid, ezetimibe, and atorvastatin NDA: 2027 Triple Combination B bempedoic acid, ezetimibe, and rosuvastatin NDA: 2027 Cardiovascular Disease (LDL-C lowering / CV Risk reduction) LDL-C: low-density lipoprotein cholesterol; CV: cardiovascular; NDA: New Drug Application; IND: Investigational New Drug Liver Diseases

Oral Triple Combination © 2025 Esperion Therapeutics, Inc. All rights reserved. 17 1. Product in development, not approved, LDL-C data based on literature evaluating co administered products (Rubino et.al Atherosclerosis 320 (2021) 122-128, Mahajan et.al. J. Clin. Lipidology (2004), Vol 18 (5) e867-872; 2. USPI for Zetia (November 2024), monotherapy and on statin; 3. New Amsterdam Pharma corporate presentation (Jan 2025); 4. USPI for Repatha (Nov 2024), Praluent (March 2024) and Leqvio (July 2024) No head-to-head studies have been conducted; cross-study data reflect different study designs, populations, and other features. Approval Status LDL-C reduction Administration Dosing In development ~ 60% - 70% Once daily Triple Combo1 Approved/Generic 19% Once daily In development 33% Once daily 3 approved products ~ 48% - 71% Bi-weekly to 6 months Ezetimibe2 Obicetrapib3 PCSK9i4 Oral CETP inhibitor not approved with unknown safety profile. No proven CV RR data. PCSK9i products are injectable.

PSC: High Unmet Medical Need Driving Significant Market Opportunity 18 © 2025 Esperion Therapeutics, Inc. All rights reserved. 2024 Diagnosed Prevalence of PSC US EU 1. Bakhshi Z, et al. J Gastroenterol. 2020 May;55(5):523-532.; 2. Nguyen A, et al. Front Gastroenterol (Lausanne). 2022;1:1076788.; 3. Liang H, et al. Medicine (Baltimore). 2017;96(24):e7116.; 4. Boonstra K, et al. Hepatology. 2013;58(6):2045-55.; 5. Krampe, J, et al. Poster presented at: ISPOR 2024; Nov 2, 2024; Barcelona, Spain Annual Market Opportunity Estimate • No approved therapies with proven efficacy to cure or halt PSC progression • High healthcare burden from hospitalization, transplants, and long-term management costs • Death or liver transplantation expected within 1- 2 decades after diagnosis • Potential Orphan Drug Designation & Fast Track Approval • Discovery program is internally developed and wholly-owned globally PSC: A Rare and Progressive Liver Disease 30K3-5 >$1B 46K1-2 ~76K PSC: primary sclerosing cholangitis

Development Timeline 2025 2026 Early 2030’s Pre-IND Interactions with FDA Pre-Clinical IND-Enabling Studies IND Filing Phase 1 Clinical Studies Commercialization / Market Launch FDA: Food and Drug Administration IND Enabling Clinical Development Registration/Launch Candidate Nomination Discovery 19 © 2025 Esperion Therapeutics, Inc. All rights reserved.

Experienced Leaders, Breakthrough Results 20 © 2025 Esperion Therapeutics, Inc. All rights reserved. Sheldon Koenig PRESIDENT AND CHIEF EXECUTIVE OFFICER Glenn Brame CHIEF TECHNICAL OPERATIONS OFFICER Betty Jean Swartz CHIEF BUSINESS OFFICER Ben Looker, Esq. GENERAL COUNSEL Ben Halladay CHIEF FINANCIAL OFFICER Stephen Pinkosky VP, EARLY & PRE-CLINICAL DRUG DISCOVERY LeAnne Bloedon VP, CLINICAL DEVELOPMENT Heather Persh VP, HUMAN RESOURCES Satish Nachaegari VP, GLOBAL REGULATORY AFFAIRS

Appendix

Significantly Differentiated from Potential Competitors © 2025 Esperion Therapeutics, Inc. All rights reserved. 22 Commercially Available Bempedoic Acid1 (alone and in combination with ezetimibe) CV Risk Reduction MACE-4: -13% MACE-3: -15% CV Risk Reduction in Primary Prevention MACE-4: -32% MACE-3: -39% FDA Approved for CV Risk Reduction Safety & Tolerability Demonstrated safety in 9,000+ patients across Phase 3 clinical trials Primary & Secondary Prevention Obicetrapib: Not available (Q4 2026*) Torceptrapib: +25%3 Dalcetrapib & Evacetrapib: No change4-5 Anacetrapib: -9%6 CETPi Long-term safety of obicetrapib not established2 Safety concerns halted dev. on 4 previous CETPis due to ↑ death & CV risk, clinical futility and fat tissue accumulation3-6 Concern for macular degeneration from genetic studies7 Not planned Bempedoic acid: -17-20% Bempedoic acid + ezetimibe: -38% LDL-C Lowering Obicetrapib: -33-35%2 Torceptrapib: -25%3 Dalcetrapib: No difference4 Evacetrapib: -37%5 Anacetrapib: -40%6 CETPi: cholesterol ester transfer protein; MACE-4: CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization; MACE-3: CV death, nonfatal myocardial infarction, or nonfatal stroke 1. Nexletol (bempedoic acid) Tablets [Package Insert]; Nexlizet (bempedoic acid and ezetimibe) [Package Insert] Ann Arbor, MI: Esperion Therapeutics, Inc.; 2. New Amsterdam Pharma Conference Call Presentation December 10, 2024. 3. N Engl J Med. 2007;357:2109–22; 4. N Engl J Med. 2012;367:2089–99; 5. N Engl J Med. 2017;376:1933–1942; 6. N Engl J Med. 2017;377:1217–1227.; 7. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:7401–6 Esperion has not conducted any head-to-head studies comparing its product candidates to any third party drug products or candidates, whether investigated or approved. Information regarding other drug products in this presentation is meant to provide context for illustrative purposes only. Because there are no head-to-head studies, no conclusions should be made based on cross study comparisons. *estimated trial primary completion date

Significantly Differentiated from Potential Competitors cont. © 2025 Esperion Therapeutics, Inc. All rights reserved. 23 Commercially Available Bempedoic Acid1 (alone and in combination with ezetimibe) CV Risk Reduction MACE-4: -13% MACE-3: -15% Not available (Q3 2029*) PCSK9i [enlicitide decanoate (MK-0616)] CV Risk Reduction in Primary Prevention MACE-4: -32% MACE-3: -39% FDA Approved for CV Risk Reduction Safety & Tolerability Demonstrated safety in 9,000+ patients across Phase 3 clinical trials Primary & Secondary Prevention Administration Oral • Oral (requires fasting 8 hours prior and 30 minutes after) • 50% decrease in bioavailability and absorption with food2 Long-term safety is not established Not available LDL-C Lowering Bempedoic acid: -17-20% Bempedoic acid + ezetimibe: -38% -60%2 PCSK9i: proprotein convertase subtilisin/kexin type 9; MACE-4: CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization; MACE-3: CV death, nonfatal myocardial infarction, or nonfatal stroke 1. Nexletol® (bempedoic acid) Tablets [Package Insert]. Ann Arbor, MI: Esperion Therapeutics, Inc.; 2. J Am Coll Cardiol. 2023 Apr 25;81(16):1553-1564. Esperion has not conducted any head-to-head studies comparing its product candidates to any third party drug products or candidates, whether investigated or approved. Information regarding other drug products in this presentation is meant to provide context for illustrative purposes only. Because there are no head-to-head studies, no conclusions should be made based on cross study comparisons. *estimated trial primary completion date

Important Safety Information

NEXLETOL® (bempedoic acid) Important Safety Information 25 © 2025 Esperion Therapeutics, Inc. All rights reserved. • NEXLIZET is indicated: • The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: • established cardiovascular disease (CVD), or • at high risk for a CVD event but without established CVD. • As an adjunct to diet: • NEXLIZET, alone or in combination with other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. • NEXLETOL, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. • NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred. • Hyperuricemia: NEXLETOL may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. • Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture. • The most common adverse reactions in the primary hyperlipidemia trials of NEXLETOL in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. • The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis. • Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLETOL. • Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633. See full prescribing information here.

NEXLIZET® (bempedoic acid and ezetimibe) Important Safety Information 26 © 2025 Esperion Therapeutics, Inc. All rights reserved. • NEXLIZET is indicated: • The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: • established cardiovascular disease (CVD), or • at high risk for a CVD event but without established CVD. • As an adjunct to diet: • NEXLIZET, alone or in combination with other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. • NEXLETOL, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. • NEXLIZET is contraindicated in patients with a prior hypersensitivity to ezetimibe or bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as anaphylaxis, angioedema, rash, and urticaria have been reported with ezetimibe or bempedoic acid. • Hyperuricemia: Bempedoic acid, a component of NEXLIZET, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. • Tendon Rupture: Bempedoic acid, a component of NEXLIZET, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLIZET at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture. • The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid (a component of NEXLIZET) in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. • Adverse reactions reported in ≥2% of patients treated with ezetimibe (a component of NEXLIZET) and at an incidence greater than placebo in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza. • In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence ≥3% and greater than placebo) observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, were urinary tract infection, nasopharyngitis, and constipation. • The most common adverse reactions in the cardiovascular outcomes trial of bempedoic acid (a component of NEXLIZET) at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis. • Discontinue NEXLIZET when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLIZET. • Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633. See full prescribing information here.